全文获取类型
收费全文 | 38114篇 |
免费 | 2463篇 |
国内免费 | 106篇 |
专业分类
耳鼻咽喉 | 295篇 |
儿科学 | 1263篇 |
妇产科学 | 1035篇 |
基础医学 | 4308篇 |
口腔科学 | 603篇 |
临床医学 | 6632篇 |
内科学 | 6712篇 |
皮肤病学 | 403篇 |
神经病学 | 3660篇 |
特种医学 | 784篇 |
外国民族医学 | 1篇 |
外科学 | 3824篇 |
综合类 | 404篇 |
现状与发展 | 1篇 |
一般理论 | 66篇 |
预防医学 | 5248篇 |
眼科学 | 495篇 |
药学 | 2282篇 |
中国医学 | 35篇 |
肿瘤学 | 2632篇 |
出版年
2023年 | 212篇 |
2022年 | 371篇 |
2021年 | 695篇 |
2020年 | 486篇 |
2019年 | 757篇 |
2018年 | 927篇 |
2017年 | 638篇 |
2016年 | 717篇 |
2015年 | 762篇 |
2014年 | 1139篇 |
2013年 | 1811篇 |
2012年 | 2552篇 |
2011年 | 2721篇 |
2010年 | 1450篇 |
2009年 | 1272篇 |
2008年 | 2473篇 |
2007年 | 2660篇 |
2006年 | 2478篇 |
2005年 | 2474篇 |
2004年 | 2300篇 |
2003年 | 2201篇 |
2002年 | 2113篇 |
2001年 | 454篇 |
2000年 | 400篇 |
1999年 | 485篇 |
1998年 | 450篇 |
1997年 | 382篇 |
1996年 | 314篇 |
1995年 | 339篇 |
1994年 | 276篇 |
1993年 | 256篇 |
1992年 | 315篇 |
1991年 | 322篇 |
1990年 | 308篇 |
1989年 | 274篇 |
1988年 | 256篇 |
1987年 | 243篇 |
1986年 | 215篇 |
1985年 | 228篇 |
1984年 | 214篇 |
1983年 | 214篇 |
1982年 | 205篇 |
1981年 | 200篇 |
1980年 | 171篇 |
1979年 | 126篇 |
1978年 | 141篇 |
1977年 | 100篇 |
1976年 | 67篇 |
1975年 | 58篇 |
1974年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Measles is a highly contagious disease caused by measles virus and is one of the most devastating infectious diseases of man--measles was responsible for millions of deaths annually worldwide before the introduction of the measles vaccines. Remarkable progress in reducing the number of people dying from measles has been made through measles vaccination, with an estimated 164,000 deaths attributed to measles in 2008. This achievement attests to the enormous importance of measles vaccination to public health. However, this progress is threatened by failure to maintain high levels of measles vaccine coverage. Recent measles outbreaks in sub-Saharan Africa, Europe, and the USA show the ease with which measles virus can re-enter communities if high levels of population immunity are not sustained. The major challenges for continued measles control and eventual eradication will be logistical, financial, and the garnering of sufficient political will. These challenges need to be met to ensure that future generations of children do not die of measles. 相似文献
993.
994.
Lucas G Win N Calvert A Green A Griffin E Bendukidze N Hopkins M Browne T Poles A Chapman C Massey E 《Vox sanguinis》2012,103(1):10-17
Background and Objectives Transfusion‐related acute lung injury (TRALI) is associated with the passive transfusion of leucocyte antibodies in blood products. Blood Transfusion Services have adopted a number of different strategies for reducing the incidence of TRALI, but, while these have been successful, TRALI has not been completely eliminated. Many Transfusion Services have introduced leucocyte antibody screening of donors to further reduce TRALI. This report describes the results of donor leucocyte antibody screening within NHS Blood and Transplant and the guidelines that have been developed for Transfusion Services within the United Kingdom (UK) to reduce the incidence of TRALI. Materials and Methods Blood samples from newly recruited female apheresis donors were tested for human leucocyte antigens (HLA) class I and class II antibodies and granulocyte‐specific antibodies. Results A total of 1157 female donors were evaluated. Three hundred and fifteen (27·23%) donors had HLA class I or II antibodies and were returned to red cell component donation. Fifty‐seven (6·77%) of the remaining 842 donors were found to have granulocyte‐specific antibodies of which 11 (1·31%) had HNA‐specific antibodies. A total of 818 donors (70·70%) were accepted for platelet apheresis, 336 donors (29·04%) were returned to red cell component donation, and three donors with HNA‐3a antibodies (0·26%) were deferred from therapeutic donation. Conclusions Female donors with leucocyte antibodies were identified in a stratified screening programme. Donors with antibodies were either directed to red cell donation or deferred. This process, combined with other measures that have already been introduced, is anticipated to further reduce the incidence of TRALI. 相似文献
995.
996.
997.
Sandy S. Chang Carlos O. WeissQian-Li Xue Linda P. Fried 《Archives of gerontology and geriatrics》2012,54(1):9
Frailty is associated with a pro-inflammatory state, which has been characterized by elevated levels of systemic inflammatory biomarkers, but has not been related to the number of co-existing chronic diseases associated with inflammation. We sought to determine the extent to which a higher number of inflammatory-related diseases is associated with frailty and to identify the most common disease patterns associated with being frail in older adults. We performed binomial regression analyses to assess whether a higher count of inflammatory-related diseases increases the probability of frailty using data from the WHAS I and II, companion cohorts composed of 70-79-year-old community-dwelling older women in Baltimore, Maryland (n = 620). An increase of one inflammatory-related disease was associated log-linearly with frailty (Prevalence Ratio (PR) = 2.28, 95% Confidence Interval (CI) = 1.81-2.87). After adjusting for age, race, education, and smoking status, the probability of frailty remained significant (PR = 1.97, 95%CI = 1.52-2.55). In the frail population, chronic kidney disease (CKD) and depressive symptoms (Prevalence = 22.9%, 95%CI = 14.2-34.8%); CVD and depressive symptoms (21.7%, 95%CI = 13.2-33.5%); CKD and anemia (18.7%, 95%CI = 11.1-29.7%); cardiovascular disease (CVD), CKD, and pulmonary disease (10.7%, 95%CI = 5.2-21.0%); CKD, anemia, and depressive symptoms (8.7%, 95%CI = 3.9-18.2%); and CVD, anemia, pulmonary disease, and depressive symptoms (5.0%, 95%CI = 1.6-14.4%) were among the most frequent disease combinations. Their prevalence percentages were significantly higher in the frail versus non-frail women. A higher inflammatory-related disease count, perhaps reflecting a greater pro-inflammatory burden, increases the likelihood of frailty. Shared mechanisms among specific disease combinations may further contribute to this risk. 相似文献
998.
Pawar PP Jones LG Feller M Guichard JL Mujib M Ahmed MI Roy B Rahman T Aban IB Love TE White M Aronow WS Fonarow GC Ahmed A 《Archives of gerontology and geriatrics》2012,55(1):85-90
Tobacco smoking is a risk factor for atrial fibrillation (AF), but little is known about the impact of smoking in patients with AF. Of the 4060 patients with recurrent AF in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 496 (12%) reported having smoked during the past two years. Propensity scores for smoking were estimated for each of the 4060 patients using a multivariable logistic regression model and were used to assemble a matched cohort of 487 pairs of smokers and nonsmokers, who were balanced on 46 baseline characteristics. Cox and logistic regression models were used to estimate the associations of smoking with all-cause mortality and all-cause hospitalization, respectively, during over 5 years of follow-up. Matched participants had a mean age of 70 ± 9 years (± S.D.), 39% were women, and 11% were non-white. All-cause mortality occurred in 21% and 16% of matched smokers and nonsmokers, respectively (when smokers were compared with nonsmokers, hazard ratio=HR=1.35; 95% confidence interval=95%CI=1.01-1.81; p=0.046). Unadjusted, multivariable-adjusted and propensity-adjusted HR (95% CI) for all-cause mortality associated with smoking in the pre-match cohort were: 1.40 (1.13-1.72; p=0.002), 1.45 (1.16-1.81; p=0.001), and 1.39 (1.12-1.74; p=0.003), respectively. Smoking had no association with all-cause hospitalization (when smokers were compared with nonsmokers, odds ratio=OR=1.21; 95%CI=0.94-1.57, p=0.146). Among patients with AF, a recent history of smoking was associated with an increased risk of all-cause mortality, but had no association with all-cause hospitalization. 相似文献
999.
1000.
Thenappan T Swamy R Shah A Nathan S Nichols J Bond L Jolly N 《The American journal of cardiology》2012,109(9):1379-1382
Significant variability in activated clotting time (ACT) measurement exists based on the type of point-of-care system used. We sought to determine the degree of agreement in ACT measurements by the Hemochron Response and the Hemochron Signature Elite Whole Blood coagulation systems and whether these 2 systems can be used interchangeably. We prospectively compared 126-paired samples in 77 patients undergoing percutaneous coronary intervention. ACT was measured for each sample using the Hemochron Response system with glass test tubes and the Hemochron Signature Elite system with low-range ACT cuvettes simultaneously. We used correlation and Bland-Altman analyses. Mean age of the study cohort was 67 ± 11 years, 49% were women, and 65% of measurements were made after systemic anticoagulation. There was a significant correlation between the Hemochron Response and Hemochron Signature Elite systems (r = 0.84, p <0.01). However, the mean bias for the ACT measurement was 9 seconds (95% confidence interval -69 to 86). In the therapeutic range of ACT measurements, the mean bias was 15 seconds (95% confidence interval -60 to 91). Thirty-three percent of total samples had >10% disagreement and 8% of samples had >20% disagreement in the ACTs measured with the Hemochron Response compared to the Hemochron Signature Elite. In conclusion, the Hemochron Response and Hemochron Signature Elite ACT values cannot be used interchangeably. Institutions using these 2 devices should be cognizant of this difference for ensuring patient safety. 相似文献